Healthcare & Life Sciences: Drug Pricing Digest - December 2021 #2

Latham & Watkins LLP

Drug Pricing Initiatives: President Biden has indicated that a Senate vote on H.R. 5376 (the Build Back Better Act, or BBBA) will likely not occur until 2022. This follows conversations between President Biden and Senator Joe Manchin, who is being described as the primary Democratic holdout. The BBBA is an approximately $2.2 trillion social safety net, climate, and tax bill that includes measures related to drug pricing and healthcare. The House of Representatives passed the BBBA on Nov. 19, 2021.

The BBBA is part of the budget reconciliation process, which allows passage in the Senate by a simple majority. Passage would require all 50 Democratic and Independent Senators’ votes, with Vice President Harris casting the tie-breaking vote. No Republican Senators are expected to support the measure.

Please see full Publication below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Latham & Watkins LLP | Attorney Advertising

Written by:

Latham & Watkins LLP

Latham & Watkins LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.